Trial · NCT07884877
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
NCT07884877, Phase 2, Recruiting, Samsung Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer. Trials, record NCT07884877. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884877
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
- NCT number
- NCT07884877
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 38 participants, estimated
- Lead sponsor
- Samsung Medical Center
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy
- Interventions
- PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 12-Month Progression-Free Survival Rate | 12 months from start of radiotherapy | Proportion of participants alive without progression (RECIST v1.1) or death at 12 months from the start of radiotherapy, estimated by the Kaplan-Meier method. |
| Secondary | Progression-Free Survival | Up to 36 months | Time from start of radiotherapy to progression (RECIST v1.1) or death from any cause, whichever occurs first; median estimated by the Kaplan-Meier method. |
| Secondary | 6-Month Progression-Free Survival Rate | 6 months from start of radiotherapy | Proportion of participants alive without progression (RECIST v1.1) or death at 6 months from the start of radiotherapy, estimated by the Kaplan-Meier method. |
| Secondary | Objective Response Rate | Up to 36 months | Proportion of participants with a best overall response of complete or partial response per RECIST v1.1. |
| Secondary | Overall Survival | Up to 36 months | Time from start of radiotherapy to death from any cause. |
| Secondary | Disease Control Rate | Up to 36 months | Proportion of participants with a best overall response of complete response, partial response, or stable disease per RECIST v1.1. |
| Secondary | Local Recurrence-Free Survival | Up to 36 months | Time from start of radiotherapy to first recurrence or progression within the irradiated lesion (PTV). |
| Secondary | Incidence of Adverse Events | Up to 36 months | Type, frequency, and severity of adverse events graded by NCI CTCAE v5.0. |
| Other | Change in Peripheral Immune Cell Subsets and Plasma Cytokines | Before each pulse and 3 months after radiotherapy | Immune phenotyping of PBMCs by flow cytometry and plasma cytokine levels (e.g., IL-6, IL-8, IL-10, IFN-gamma). |
| Other | Change in CT Radiomic Features | Before each pulse | Radiomic features extracted from planning CT before each pulse. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884877
GET https://conductscience.org/api/trials/v1/NCT07884877/registered